World
This Indian company to buy US tech giant Organon for Rs 1100000000000, share zooms, the company is…, owner is…., not Mukesh Ambani
India’s leading pharma company Sun Pharmaceutical Industries has unveiled a major acquisition, announcing plans to purchase US-based Organon & Co. in an all-cash deal worth USD 11.75 billion. This move stands among the largest overseas acquisitions ever made by an Indian firm. As per the definitive agreement, Sun Pharma will acquire all outstanding shares of Organon at USD 14 per share. The deal has received approval from the boards of both companies and is likely to be completed in early 2027, subject to regulatory approvals and shareholder consent.
Rise in Sun Pharma share price
2 / 6
Following the announcement, Sun Pharma’s stock witnessed a strong rally. Shares surged over 7%, rising 7.53% to Rs 1,742 on the BSE and 7.50% to Rs 1,742 on the NSE. The jump added Rs 27,462.59 crore to its market capitalisation, taking it to Rs 16,142.85 crore during morning trade.
About Organon
3 / 6
Organon, which was spun off from Merck & Co. (known as MSD outside the US and Canada) in 2021, is a global healthcare company with six manufacturing facilities across the European Union and emerging markets. It has a portfolio of more than 70 products across women’s health, biosimilars, and general medicines, and operates in 140 countries.
Sun Pharma in list of top 25 pharma companies
4 / 6
With this acquisition, Sun Pharma is expected to enter the list of the top 25 global pharmaceutical companies, with combined revenues reaching USD 12.4 billion. The deal will also significantly strengthen its presence in the women’s health segment, making it one of the top three players globally and the seventh-largest biosimilar company.
Financials
5 / 6
Financially, Organon reported revenue of USD 6.2 billion and adjusted EBITDA of USD 1.9 billion in 2025. It holds debt of USD 8.6 billion along with cash reserves of USD 574 million. Sun Pharma anticipates synergies exceeding USD 350 million within two to four years after completion of the deal. The merged entity will have operations in 150 countries, with at least 18 markets each generating over USD 100 million in revenue.
Among top deals
6 / 6
This acquisition joins the list of major cross-border deals by Indian companies, alongside Tata Steel’s USD 12 billion acquisition of Corus in 2007 and Bharti Airtel’s USD 10.7 billion takeover of Zain Telecom’s African business in 2010. For Sun Pharma, it adds to previous landmark deals such as the USD 4 billion acquisition of Ranbaxy in 2014 and the earlier purchase of Taro Pharmaceutical Industries in 2007. Overall, the deal is expected to significantly boost Sun Pharma’s global footprint while diversifying its portfolio, particularly in high-growth areas like women’s health and biosimilars.
